Scancell Holdings (GB:SCLP) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Scancell Holdings Plc has successfully raised £10.3 million through an oversubscribed placing, which attracted substantial interest from existing and new healthcare specialist investors. The funds will support the development of its cancer vaccine, SCIB1, and its next-generation counterpart, iSCIB1+, as the company strives to advance its clinical trials for treating advanced melanoma. This financial boost is set to extend Scancell’s cash runway into the second half of 2026, signaling robust investor confidence in its innovative immunotherapy solutions.
For further insights into GB:SCLP stock, check out TipRanks’ Stock Analysis page.